Although the inclusion criteria were limited to patients with low to low-intermediate risk prostate adenocarcinoma, differences in Gleason score and pre-treatment PSA may represent variations in the underlying biology of the prostate adenocarcinoma, and therefore affect the response to radiation. Here, KLK3 is linked to prostate adenocarcinoma.